scholarly journals PMH74 COMPARING PSYCHOMETRIC PROPERTIES OF SELF-VERSUS INTERVIEWER-RATED INSTRUMENTS USED IN CLINICAL TRIALS FOR PATIENTS WITH ANXIETY DISORDERS

2004 ◽  
Vol 7 (3) ◽  
pp. 286
Author(s):  
DT Lau ◽  
JC Cappelleri ◽  
R Morlock ◽  
D Feltner
Keyword(s):  
Clinical Trials ◽  
Anxiety Disorders ◽  
Psychometric Properties

scholarly journals Adapting Social Neuroscience Measures for Schizophrenia Clinical Trials, Part 2: Trolling the Depths of Psychometric Properties

2013 ◽  
Vol 39 (6) ◽  
pp. 1201-1210 ◽  
Author(s):  
Robert S. Kern ◽  
David L. Penn ◽  
Junghee Lee ◽  
William P. Horan ◽  
Steven P. Reise ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Psychometric Properties ◽  
Social Neuroscience

scholarly journals Psychometric properties of the Neuropsychiatric Inventory: a review

2019 ◽  
Author(s):  
Toni Saari ◽  
Anne Koivisto ◽  
Taina Hintsa ◽  
Tuomo Hänninen ◽  
Ilona Hallikainen
Keyword(s):  
Clinical Trials ◽  
Measurement Error ◽  
Construct Validity ◽  
Psychometric Properties ◽  
Outcome Measurement ◽  
Neuropsychiatric Symptoms ◽  
Practical Importance ◽  
Reliability And Validity ◽  
Small Sample ◽  
Neuropsychiatric Inventory

Neuropsychiatric symptoms (NPSs) cause a significant burden to individuals with memory disorders and their families. Insights into the clinical associations, neurobiology, and treatment of NPSs are largely dependent on informant questionnaires, such as the commonly used Neuropsychiatric Inventory (NPI). Like any scale, the utility of the NPI relies on its psychometric properties, but unlike many scales, the NPI faces unique challenges related to its skip-question and scoring formats.We examined and reviewed the psychometric properties of the NPI in a framework including psychometric properties pertinent for construct validation, and health-related outcome measurement in general. We found that aspects such as test-retest and inter-rater reliability are major strengths of the NPI in addition to its flexible and relatively quick administration. These properties are desired in clinical trials. However, it seems that the reported properties cover only some of the generally examined psychometric properties, representing perhaps necessary but not sufficient reliability and validity evidence for the NPI. There appear to be significant gaps in psychometric data, at least partially owing to small sample sizes in the studies that preclude more comprehensive analyses. Regarding construct validity, only one study examined structural validity with the NPI subquestions. Measurement error was not assessed in the reviewed studies. For future validation, we recommend using data from all subquestions, collecting larger samples, paying specific attention to construct validity and formulating hypotheses a priori. As the NPI is an outcome measure of interest in clinical trials, examining measurement error could be of practical importance.

scholarly journals Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis

RMD Open ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. e000928 ◽  
Author(s):  
Dafna Gladman ◽  
Peter Nash ◽  
Hitoshi Goto ◽  
Julie A Birt ◽  
Chen-Yen Lin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Psychometric Properties ◽  
Rating Scale ◽  
Numeric Rating Scale ◽  
Routine Clinical Practice ◽  
Patient Reported ◽  
Test Retest Reliability ◽  
Numeric Rating

ObjectivesThis study assessed the psychometric properties of the fatigue numeric rating scale (NRS) and sought to establish values for clinically meaningful change (responder definition).MethodsUsing disease-specific clinician-reported and patient-reported data from two randomised clinical trials of patients with psoriatic arthritis (PsA), the fatigue NRS was evaluated for test–retest reliability, construct validity and responsiveness. A responder definition was also explored using anchor-based and distribution-based methods.ResultsTest–retest reliability analyses supported the reproducibility of the fatigue NRS in patients with PsA (intraclass correlation coefficient=0.829). Mean (SD) values at baseline and week 2 were 5.7 (2.2) and 5.7 (2.4), respectively. Supporting construct validity of the fatigue NRS, moderate-to-large correlations with other assessments measuring similar concepts as measured by Sackett’s conventions were demonstrated. Fatigue severity was reduced when the underlying disease activity was improved and reductions remained consistent at week 12 and 24. A 3-point improvement was identified as being optimal for demonstrating a level of clinically meaningful improvement in fatigue NRS after 12–24 weeks of treatment.ConclusionsFatigue NRS is a valid and responsive patient-reported outcome instrument for use in patients with PsA. The established psychometric properties from this study support the use of fatigue NRS in clinical trials and in routine clinical practice. Robust validation of reliability for use in routine clinical practice in treating patients with active PsA in less active disease states and other more diverse ethnic groups is needed.

Sign in / Sign up

Export Citation Format

Share Document